Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Emergent BioSolutions Inc.NYSE: EBS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) declines year over year

Q1 FY2026 weighted avg shares (diluted) of 56.5M shares fell 1.4% year over year, behind the -0.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.4% toward the trailing-twelve-month pace of -0.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.5M+7.8% QoQ
Last fiscal yearDec 2025
56.7M+7.0% YoY
LTMMar 2026
54.9M-0.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.4%——
1 year+7.0%——
3-year CAGR+4.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
56.7M USD
Year-over-year change
+7.0%
4-year CAGR
+1.2%

Weighted Avg Shares (Diluted) vs competitors

How EBS compares with its peers on the latest reported figures

  • EBS's LTM Mar 2026 weighted avg shares (diluted) of 54.9M shares is the 9th highest of the 11 companies compared; the peer median is 92.66M shares.
  • Its year-over-year change of -0.0% is the 8th highest of 11, against a peer median of +13.2%.
  • Over three fiscal years its annual growth of +4.2% compares with a peer median of +12.0%.
EBS Competitors Peer median
Weighted Avg Shares (Diluted) for EBS and competitors
Company Period LTM YoY 3-year CAGR
SNDLSNDL Inc.LTM Mar 2026261.05M -0.7%+3.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026232.73M +20.1%+46.3%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026129.43M -1.4%-0.5%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
CMPSCOMPASS Pathways plcLTM Mar 202693.99M +27.7%+30.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.59M +22.4%+19.7%
SIGASIGA Technologies, Inc.LTM Mar 202671.65M -0.0%-0.9%
EBSEmergent BioSolutions Inc.LTM Mar 202654.9M -0.0%+4.2%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.96M +6.3%+3.0%
Peer median (excluding EBS) 92.66M+13.2%+12.0%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.